Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5-fluorouracil and folinic acid in locally advanced rectal cancer

Journal of B.U.ON.

Volumn 9, Issue 3, 2004, Pages 255-261

  Ziras, Nikolaos ^a   Tsoutsou, P ^a   Koliarakis, N ^a   Magdalinos, N ^a   Sarris, G ^a   Potamianou, A ^a   Paraskevaides, M ^a   Synodinou, M ^a   Chrysanthou, K ^a   Karageorgis, P ^a   Athanassiou, A E ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

5 fluorouracil; Adjuvant treatment; Irinotecan; Radiotherapy; Rectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGINA PECTORIS; ARTICLE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; ENTEROCOLITIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ILEUS; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NUTRITIONAL DISORDER; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PROCTITIS; PROGNOSIS; RADIATION DERMATITIS; RECTUM CANCER; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 20144381463     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA: A Cancer Journal for Clinicians 2001; 51: 15-36.
2. Mayer RJ. Moving beyond fluorouracil for colorectal cancer. N Engl J Med 2000; 343: 963-964.
3. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal cancer. N Engl J Med 1991; 324: 709-715.
4. Colorectal Cancer Collaboration Group: Adjuvant radiotherapy for rectal cancer: A systematic overview of 8507 patients from 22 randomized trials. Lancet 2002; 358: 1291-1304.
5. Ranghammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
6. Freyer G, Bossard N, Romestaing P et al. Addition of oxaliplatin to continuous fluorouracil, L-folinic acid and concomitant radiotherapy in rectal cancer. The Lyon R97-03 phase I trial. J Clin Oncol 2001; 19: 2433-2438.
7. Douillard JV, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal carcinoma: a multicenter randomized trial. Lancet 2000; 255: 1041-1047.
8. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal carcinoma. N Engl J Med 2000; 343: 905-914.
9. Kalofonos HP, Kardamakis D, Bamias A et al. Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study. Anticancer Res 2003; 23: 1687-1692.
10. Trotti A, Byhardt R, Stetz J et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer management: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-1142.
13. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med 2004; 350: 2406-2408.
14. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
15. Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst Rev 2002; 2: CD001545.
16. Greemers GJ, Lund B, Verweig J et al. Topoisomerases I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
17. Hartman JT, Oechsle K, Jager E et al. Prospective multicenter phase II study of irinotecan as third-line therapy for metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 2004; 15: 473-477.
18. Cunningham D, Pyrhonen S, James RD et al. A phase III multicenter randomized study of CPT-11 versus supportive care (SC) alone in patients (pts) with 5-FU resistant metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 1998; 17: 1a (abstr).
19. Pougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996; 23: 34-41.
20. Tepper JE, O'Connel MJ, Petroni GR et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic irradiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 1997; 15:2030-2039.
21. Fountzilas G, Zisiadis A, Dagni U et al. Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 671-676.
22. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
23. Tebbutt NC, Norman AR, Cunningham D et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52: 568-573.